RALEIGH, N.C.--(BUSINESS WIRE)--Jan. 24, 2006--Erimos Pharmaceuticals Inc. announced today that patient dosing has commenced for its lead product candidate, EM-1421, for the treatment of refractory and metastatic solid tumors that are unresponsive to conventional therapy. The study is being conducted at Albert Einstein College of Medicine in Bronx, N.Y.; Premiere Oncology of Scottsdale, Ariz.; and in Nashville, Tenn.
